Table 5 Clinical and echocardiographic data between survivors and non-survivors
| Â | 28d mortality | In-hospital mortality | ||||
|---|---|---|---|---|---|---|
Survivors | Non-survivors | p value | Survivors | Non-survivors | p value | |
Age (yrs) | 66 ± 16 | 65 ± 21 | 0.624 | 66 ± 16 | 67 ± 19 | 0.887 |
Sex (male, %) | 77 (65.3) | 17 (68.0) | 0.793 | 68 (63.0) | 26 (74.3) | 0.220 |
BMI (kg/m2) | 23.2 ± 3.3 | 21.6 ± 2.9 | 0.027 | 23.3 ± 3.3 | 21.8 ± 2.8 | 0.021 |
APACHE II | 16.3 ± 5.7 | 20.7 ± 7.2 | 0.001 | 15.8 ± 5.5 | 21.0 ± 6.7 |  < 0.001 |
SOFA | 6.3 ± 2.4 | 9.1 ± 2.9 |  < 0.001 | 6.2 ± 2.4 | 8.6 ± 2.8 |  < 0.001 |
Comorbidity (n, %) | 70 (59.3) | 18 (72) | 0.237 | 65 (60.2) | 27 (77.1) | 0.069 |
CVP (mmHg) | 9.1 ± 2.8 | 10.6 ± 3.3 | 0.576 | 9.2 ± 2.9 | 10.7 ± 3.5 | 0.328 |
NT-proBNP (pg/mL) | 3839 ± 610 | 8485 ± 2317 | 0.063 | 3368 ± 536 | 8609 ± 2000 | 0.016 |
CTnT (ng/mL) | 0.07 ± 0.01 | 0.13 ± 0.03 | 0.048 | 0.06 ± 0.01 | 0.11 ± 0.03 | 0.059 |
CK-MB (ng/mL) | 5.7 ± 1.0 | 10.3 ± 2.7 | 0.076 | 5.7 ± 1.0 | 8.8 ± 2.2 | 0.201 |
LVEF (%) | 57.9 ± 8.6 | 53.3 ± 11.5 | 0.070 | 58.2 ± 8.5 | 53.8 ± 10.9 | 0.034 |
GLS (%) |  − 14.1 ± 3.3 |  − 13.4 ± 4.7 | 0.475 |  − 14.2 ± 3.4 |  − 13.4 ± 4.2 | 0.322 |
MAPSE (mm) | 12.9 ± 3.8 | 11.3 ± 3.5 | 0.053 | 13.1 ± 3.8 | 11.4 ± 3.5 | 0.022 |
TMADMid (mm) | 12.1 ± 4.5 | 8.9 ± 4.1 | 0.001 | 12.2 ± 4.5 | 9.6 ± 4.2 | 0.003 |